Research Analysts Set Expectations for Absci FY2030 Earnings

Absci Corporation (NASDAQ:ABSI) – Research analysts at HC Wainwright issued their FY2030 earnings estimates for shares of Absci in a note issued to investors on Wednesday, March 25th. HC Wainwright analyst S. Ramakanth anticipates that the company will post earnings of $0.61 per share for the year. HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for Absci’s current full-year earnings is ($0.89) per share.

ABSI has been the subject of several other research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Absci in a research note on Wednesday, January 21st. Morgan Stanley lowered shares of Absci from an “overweight” rating to an “equal weight” rating and set a $4.32 price target on the stock. in a research note on Thursday, January 8th. Finally, Needham & Company LLC reissued a “buy” rating and set a $7.00 price objective on shares of Absci in a report on Wednesday. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $7.08.

Absci Stock Performance

NASDAQ:ABSI opened at $2.78 on Thursday. Absci has a 1 year low of $2.01 and a 1 year high of $5.23. The stock has a market cap of $425.40 million, a P/E ratio of -3.27 and a beta of 2.12. The stock has a 50-day simple moving average of $2.76 and a 200-day simple moving average of $3.21.

Absci (NASDAQ:ABSI) last posted its earnings results on Tuesday, March 24th. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.07). The business had revenue of $0.65 million during the quarter, compared to analysts’ expectations of $1.38 million. Absci had a negative net margin of 4,113.68% and a negative return on equity of 62.33%.

Insider Buying and Selling

In other news, CEO Sean Mcclain sold 26,761 shares of the business’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $2.99, for a total value of $80,015.39. Following the transaction, the chief executive officer owned 8,334,567 shares of the company’s stock, valued at approximately $24,920,355.33. The trade was a 0.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Andreas Busch purchased 100,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 12th. The shares were bought at an average cost of $2.29 per share, with a total value of $229,000.00. Following the completion of the acquisition, the insider owned 421,446 shares of the company’s stock, valued at approximately $965,111.34. This trade represents a 31.11% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders own 10.49% of the company’s stock.

Institutional Trading of Absci

Several hedge funds have recently made changes to their positions in the company. ARK Investment Management LLC increased its stake in shares of Absci by 3.2% during the fourth quarter. ARK Investment Management LLC now owns 12,550,799 shares of the company’s stock worth $43,802,000 after acquiring an additional 388,026 shares during the period. Vanguard Group Inc. raised its holdings in Absci by 12.9% during the third quarter. Vanguard Group Inc. now owns 7,281,918 shares of the company’s stock worth $22,137,000 after purchasing an additional 830,336 shares in the last quarter. State Street Corp lifted its position in Absci by 190.1% in the fourth quarter. State Street Corp now owns 5,990,877 shares of the company’s stock valued at $20,908,000 after purchasing an additional 3,925,926 shares during the period. Geode Capital Management LLC boosted its holdings in Absci by 6.1% in the 4th quarter. Geode Capital Management LLC now owns 3,239,623 shares of the company’s stock valued at $11,309,000 after purchasing an additional 186,708 shares in the last quarter. Finally, Ameriprise Financial Inc. boosted its holdings in Absci by 24.4% in the 3rd quarter. Ameriprise Financial Inc. now owns 3,191,011 shares of the company’s stock valued at $9,701,000 after purchasing an additional 625,451 shares in the last quarter. Institutional investors and hedge funds own 52.05% of the company’s stock.

Key Stories Impacting Absci

Here are the key news stories impacting Absci this week:

• Positive Sentiment: HC Wainwright maintained a “Buy” rating and an $8.00 price target and published an optimistic long‑term FY2030 EPS projection ($0.61), signaling conviction in Absci’s multi‑year growth story and providing upside support for the shares.
• Positive Sentiment: Needham & Company issued a Buy rating on Absci, giving additional independent analyst support that can help stabilize sentiment. Article Title
• Neutral Sentiment: Earnings call transcript coverage is available; the Q4 2025 call and accompanying commentary give detail on product programs and cash usage that investors should read to evaluate near‑term execution. MSN Transcript Yahoo Transcript
• Neutral Sentiment: Recent coverage flags Absci’s cash‑burn situation as a watch item — this is informational but its impact depends on runway, financing options and upcoming milestones. Cash Burn Article
• Negative Sentiment: HC Wainwright sharply reduced near‑term EPS estimates across multiple quarters and fiscal years (e.g., FY2026 EPS cut from about ($0.45) to ($0.87); Q1–Q4 2026 and FY2027–2029 estimates were also lowered). Those downgrades increase short‑term uncertainty and pressure the stock.
• Negative Sentiment: Seeking Alpha published a downgrade to “Hold,” citing a shift in clinical priorities (ABS‑101 deprioritized, pivot to ABS‑201) that raises execution risk and timeline uncertainty. That sell‑side/independent downgrading contributed to negative sentiment. Seeking Alpha
• Negative Sentiment: Pre‑market coverage noted Absci among stocks moving lower, reflecting intraday selling pressure following the analyst revisions and downgrade. Pre-market Article

About Absci

Absci Corporation (NASDAQ: ABSI) is a biotechnology company that applies machine learning, synthetic biology and automation to accelerate the discovery and development of protein-based therapeutics. The company’s Integrated Drug Creation® (IDC®) platform is designed to identify and produce novel antibody and enzyme candidates at speeds and scales that traditional biopharma discovery methods cannot match. Absci works with pharmaceutical and biotechnology partners to generate, screen and optimize protein molecules for a wide range of therapeutic applications.

The core of Absci’s offering is its end-to-end discovery engine, which combines proprietary algorithms, high-throughput laboratory automation and a deep learning framework.